*Read Disclaimer Sponsored Content
October 28, 2026 | Unsubscribe
Hello!
New Alert: BioStem Technologies Inc. (NASDAQ: BSEM)
BSEM is our new Nasdaq high growth alert.
This is a hidden gem opportunity that almost no one has seen yet. The company just started trading on the NASDAQ in August.
BSEM could be positioned for a big breakout opportunity.
BSEM is a NASDAQ listed “leading regenerative medicine company”.
BSEM is “focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue.”
The company leverages its “industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings”.
Its “allografts are used by clinicians across a wide range of specialties.”
BSEM has a “growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint”.
BSEM’s “growing intellectual property portfolio”, “includes more than 100 patents and patent applications worldwide”.
BSEM is targeting one of the largest and most underserved segments in medical technology.
The company’s mission is “To create and deliver the most advanced wound healing technologies in the world” – “In Relentless Pursuit of Healing”.
The opportunity here is substantial.
BSEM is pursuing a “Large and Underserved ~$23B US Soft Tissue Allograft Opportunity” by “Driving adoption of perinatal tissue allografts for multiple market segments”.
That 23 billion market spans six segments:
Orthopedics/Sports Medicine
Chronic Wound Care
Foot & Ankle
Urology/ Colorectal
Spine
Women’s Health
The clinical and economic need is severe.
Sadly, there are approximately “155,000 lower limb amputations annually” and approximately “800,000 DFU hospitalizations annually”.
Infections and complications “cost the health system an estimated $30B+ each year”.
Perinatal Allografts address this by promoting faster healing, minimizing scarring and adhesion, preventing infection, pain management and reducing complications versus standard of care.
BSEM's has these advantages:
“Experienced National Sales Force” with “> 25 direct reps and >30 independent agents plus GPO contracts”
“Unparalleled Technical Data” with “400+ publications across all technologies and products”
“World-Class Manufacturing Capabilities” with “Experienced in-house manufacturing with ability to scale and produce historically industry leading margins”
“Expanded Addressable Market” with “End markets now include surgical applications in facility settings, including commercially insured population”
BSEM’s “quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics ("AATB").”
“These systems and procedures are established in compliance with current Good Tissue Practices ("cGTP") and current Good Manufacturing Practices ("cGMP").”
The company’s “portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines”.
The clinical results are compelling.
For instance, BSEM has “Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers” where “The probability of healing in the BR-AC arm was 53% while the probability of healing in the standard of care arm was 31%”.
Furthermore, “In a competitive study, the BR-AC arm required 2.7 fewer applications and 9.1 less treatment days for closure compared to the market leader”.
In the Ambulate study of the “most severe chronic wounds”, the company reported “66% closure at 26 weeks”.
The company has announced multiple accomplishments recently.
Earlier this year, the company announced:
“BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business”
Here are some of the company’s comments from this press release:
"This acquisition is a natural strategic fit that underscores BioStem's commitment to leading the field of advanced wound care. It provides an immediate foothold in hospital-based applications and expands our technology portfolio with an additional platform designed to optimize the preservation of both placental and umbilical tissue allografts," said Jason Matuszewski, CEO and Chairman of BioStem. "This acquired technology opens meaningful entry into high-value adjacent market segments, from acute surgical wounds to burns and soft-tissue repair, while creating synergies that enhance our entire product suite and diversify our revenue streams. BioTissue's broad and innovative surgical portfolio, robust pipeline, and highly skilled sales force, combined with BioStem's reach and operational strengths, uniquely position us to address patient needs across the spectrum of acute and chronic wound care. I am excited to welcome the impressive team of BioTissue employees to further our mission of delivering the most advanced wound healing technologies in the world."
In July, the company announced:
“BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies”
BSEM “announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies.”
“The newly issued patents strengthen BioStem's intellectual property portfolio and provide additional protection for innovative allograft designs in surgical and wound care applications.”
Here are some of the company’s comments from this press release:
"These newly issued patents represent another important step in strengthening the intellectual property foundation supporting our placental-derived allograft technologies," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "Protecting the innovations behind our products helps support our long-term growth strategy while reinforcing our commitment to advancing regenerative medicine through differentiated technologies designed to improve patient care."
As the company further explains:
“The four patents further expand BioStem's growing intellectual property portfolio, which includes more than 100 patents and patent applications worldwide.”
“BioStem continues to invest in innovation across placental tissue processing, preservation technologies, and allograft designs as it develops next-generation products for wound care and surgical applications.”
“BioStem's proprietary processing technologies are designed to optimize preservation of the innate structural and biological characteristics of placental tissues, supporting their use in a variety of clinical applications, including surgical and wound care procedures.”
In August, the company announced:
“BioStem Technologies Announces Nasdaq Uplisting”
Jason Matuszewski, Chairman and CEO of BioStem stated:
"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We believe this uplisting will expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent as we continue to grow. We are deeply grateful to our partners, investors, and stakeholders for their continued support throughout this process."
In addition, the company also announced:
“BioStem Technologies Reports Second Quarter 2026 Financial Results”
Recent Corporate Highlights
Completed the uplisting of the Company's common stock to the Nasdaq Capital Market on August 7, 2026
Completed a $2.5 million private placement with the Company's first institutional investor
Recent Business Highlights
Generated net revenue of $7.9 million for the second quarter of 2026, representing sequential growth of 29% from $6.1 million in the first quarter of 2026
Continued to scale the commercial organization, expanding the direct sales force, integrating the CRM and ERP systems, and transitioning all major group purchasing organization (GPO) agreements to broaden access across hospital systems nationwide
Issued eight new U.S. design patents covering fenestrated human placental allograft technology, further expanding the Company's intellectual property portfolio
Here are some of the company’s comments from this press release:
"The recent completion of our uplisting to Nasdaq was a monumental capital markets milestone for BioStem. This achievement enhances our visibility, broadens our access to institutional capital, and reflects the significant work our team has done to strengthen the foundation of the Company," said Jason Matuszewski, Chair and CEO of BioStem. "The second quarter marked a period of meaningful execution as we advanced the integration of new assets into our business, expanded our commercial organization, and strengthened the platform needed to support long-term growth. This progress, alongside our capital markets achievements, positions us well to sustained long-term growth."
In September, the company announced:
“BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier”
BSEM “announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation's largest Group Purchasing Organizations (GPOs). The products are available for order under both contracts effective immediately, marking the first GPO contract coverage for VENDAJE and VENDAJE AC.”
Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies commented:
"Opening hospital access for VENDAJE and VENDAJE AC is a significant step in expanding patient access to BioStem's BioRetain® wound care solutions," said Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies. "Clinicians in Vizient and Premier member hospitals can now reach for these products through their existing contracting channels, which removes a barrier that has limited where they could be used. These agreements position us to reach health systems and providers at scale and support the execution of our commercial strategy. We're pleased to build on our relationships with both organizations and to continue delivering value to hospitals, clinicians, and the patients they serve."
As the company further explains:
“Vizient is the largest GPO in the United States by affiliated staffed beds, serving more than 5,000 hospitals, and Premier is the second largest, serving more than 4,000, according to figures published by the organizations.
VENDAJE® and VENDAJE AC® are placental-derived, minimally manipulated dehydrated tissue allografts that serve as a protective covering for soft tissue wounds. VENDAJE is composed of the amnion layer of the placental membrane. VENDAJE AC is a thicker, multilayer allograft retaining the amnion, intermediate, and chorion layers. Both products are manufactured using BioStem's proprietary BioRetain® process, which is designed to retain the native properties of placental tissue.”
In September, the company also announced:
“BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility”
“BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules”
In October, the company announced:
“BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio”
“Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies”
Here are some of the comments from this press release:
"Investing in our intellectual property remains a priority for BioStem, and this patent and four allowances reflect the progress of that effort," said Jason Matuszewski, Chair and CEO of BioStem Technologies. "We plan to continue to commit resources to expanding and defending our patent estate, both in the U.S. and internationally, so that the technologies we develop stay protected as we grow our product offerings for clinicians and their patients."
In addition, the company also announced:
“BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options”
BSEM “announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at an exercise price of $2.00 per share, for a total of 500,000 shares and an aggregate purchase price of approximately $1 million.”
Here are some of the comments from this press release:
"This is an exciting and important time for the Company," said Mr. Matuszewski. "Hospitals are increasingly seeking wound care and surgical solutions that are clinically supported, reliably supplied, and economically sensible and we believe we have built one of the broadest perinatal allograft portfolios in the industry to meet exactly that need. Exercising these options reflects my continued confidence in the Company, our team and the potential for our technology. I believe this capital will support broader sales coverage, expanded hospital formulary coverage, and the inventory needed to support new accounts. I am proud to reiterate my support and remain highly committed to creating long-term value for fellow shareholders."
"Our role on the operations side is to help ensure that growth does not outpace our ability to deliver, and we've built BioStem with that objective in mind," said Mr. Van Vurst. "I see the progress every day, in our production, quality processes, and supply planning. We believe the additional capital will help support the inventory and infrastructure needed to serve new hospital accounts, and we remain focused on consistent execution for the customers and patients who rely on our products."
BSEM could be positioned for significant upside.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher expect to be compensated nine thousand dollars by bank wire transfer on 10/28/26 for the distribution of this advertisement about BSEM dated 10/28/26. Previously, owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 8/13/26 for the distribution of a prior advertisement about BSEM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.